PolyPid (PYPD) Q2 2026 Earnings Call: D-PLEX100 Priority Review and Azurity DealTradingKey·Aug 14 at 03:36 AMPYPD-0.98%
PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPSMarket Beat·Aug 12 at 12:11 PMPYPD-0.98%
PYPD: FDA accepted NDA for D-PLEX 100; $30M milestone secured, cash runway projected into 2028Quartr·Aug 12 at 06:40 AMPYPD-0.98%
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsUnusual Whales·Aug 12 at 06:32 AMPYPD-0.98%
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Expands By 235.2%Market Beat·Jul 26 at 06:00 PMPYPD-0.98%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Jul 21 at 12:05 PMTELO-4.20%CPHI+2.03%
PolyPid shares are trading lower. The company announced it has entered into an exclusive commercial partnership agreement with Azurity Pharmaceuticals for the commercialization of D-PLEX100.benzinga_article·Jul 21 at 09:30 AMPYPD-0.98%
PolyPid Locks in a Transformative Deal Worth Over $320 Million, With Additional Major Royalty Potentialbusinessinsider·Jul 21 at 08:00 AMPYPD-0.98%
PolyPid Strikes Azurity Commercialization Deal for D-PLEX100 in U.S. and CanadaTip Ranks·Jul 21 at 06:57 AMPYPD-0.98%
